zurück

Cabozantinib (new indication: thyroid carcinoma, pretreated patients, refractory to radioactive iodine)


Subject:

  • Active Substance: Cabozantinib
  • Name: Cabometyx®
  • Therapeutic area: Thyroid carcinoma
  • Pharmaceutical company: Ipsen Pharma GmbH


Time table:

  • Start: 01.06.2022
  • Final decision by G-BA: 01.12.2022


Final decision:

  • No additional benefit proved